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Abstract Human chorionic gonadotropin (hCG) is a
pregnancy-specific hormone that regulates placental
development. hCG concentrations vary widely throughout
gestation and differ based on fetal sex. Abnormal hCG
concentrations are associated with adverse pregnancy out-
comes including fetal growth restriction. We studied the
association of hCG concentrations with fetal growth and
birth weight. In addition, we investigated effect modifica-
tion by gestational age of hCG measurement and fetal sex.
Total serum hCG (median 14.4 weeks, 95 % range
10.1–26.2), estimated fetal weight (measured by ultrasound
during 18–25th weeks and[25th weeks) and birth weight
were measured in 7987 mother–child pairs from the Gen-
eration R cohort and used to establish fetal growth. Small
for gestational age (SGA) was defined as a standardized
birth weight lower than the 10th percentile of the study
population. There was a non-linear association of hCG with
birth weight (P = 0.009). However, only low hCG con-
centrations measured during the late first trimester (11th
and 12th week) were associated with birth weight and
SGA. Low hCG concentrations measured in the late first
trimester were also associated with decreased fetal growth
(P = 0.0002). This was the case for both male and female
fetuses. In contrast, high hCG concentrations during the
late first trimester were associated with increased fetal
growth amongst female, but not male fetuses. Low hCG in
the late first trimester is associated with lower birth weight
due to a decrease in fetal growth. Fetal sex differences
exist in the association of hCG concentrations with fetal
growth.
Keywords hCG  Fetal growth  Birth weight  Fetal sex 
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Introduction
Optimal intrauterine conditions are essential for proper
fetal development and growth. Intrauterine conditions are
highly dependent on the placental function since the pla-
centa is the main source of fetal nourishment and the main
regulator of the intrauterine environment [1, 2]. A subop-
timal intrauterine environment leads to fetal adaptations
that may affect fetal growth and thereby lead to lower birth
weight [3, 4]. Low birth weight is an important determinant
of child’s health and a major risk factor for several non-
communicable diseases later in life including coronary
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heart disease, stroke, hypertension and type 2 diabetes
[5, 6].
Human chorionic gonadotropin (hCG) is a pregnancy-
specific hormone that is produced by trophoblast cells from
the time of embryo implantation onwards [7]. Besides
promoting progesterone production by corpus luteal cells,
hCG has been shown to regulate many processes that are
related to fetal growth including trophoblast differentiation,
uterine growth, various aspects of placentation as well as
uterine angiogenesis and vasculogenesis [7, 8]. More
specifically, hCG has also been shown to stimulate the
production of endocrine gland-derived vascular endothelial
growth factor (EG-VEGF), which is involved in the
physiology of placental development [9, 10]. By acting on
cytotrophoblast cells, EG-VEGF is involved in the process
of trophoblast shell and arterial plugs formation, necessary
for preventing maternal blood flow into the intervillous
space during early pregnancy [9]. hCG may also directly
influence uterine and fetal growth by acting on gonado-
tropin receptors present in the uterine tissue and fetal
membranes [8, 11, 12].
Although clinical studies have shown that hCG is
associated with adverse outcomes, this association seems to
differ according to the gestational age at which hCG is
measured. Low hCG concentrations in the first trimester as
well as high hCG concentrations in the second trimester
have both been associated with pregnancy loss and
preeclampsia [13–16]. High hCG concentrations in the
second trimester have also been associated with gestational
hypertension, fetal growth restriction, fetal death and pre-
term delivery [16, 17]. Given that hCG concentrations vary
throughout gestation, it is remarkable that very little is
known about potential gestational time-dependent effects
of hCG on adverse pregnancy outcomes.
Given the important role of hCG in many fetal growth-
related processes, we examined the overall and gestational
age-dependent associations of hCG with fetal growth, as
well as possible fetal sex-specific differences, in a large
population-based prospective cohort study.
Materials and methods
Study population
This study was embedded in the Generation R cohort, a
population-based prospective study from early fetal life
onwards in Rotterdam, the Netherlands [18]. The study was
designed to identify early environmental and genetic cau-
ses leading to normal and abnormal growth, development
and health during fetal life and childhood [18]. In total,
8879 mothers with expected delivery date between April
2002 and January 2006 were enrolled during pregnancy.
Total hCG was determined in all first available serum
samples and this data, together with data on birth weight,
was available in 7987 mother–child pairs. Women with
twin pregnancies (N = 90) or in vitro fertilization treat-
ment (N = 38) were excluded from the analysis.
hCG measurements
Total hCG was measured in serum using a solid-phase two-
site chemiluminiscent immunometric assay, calibrated
against WHO 3rd IS 75/537, on an Immulite 2000 XPi
system (Siemens Healthcare Diagnostics, Deerfield, IL,
USA). The assay detects serum intact hCG, hypergly-
cosated hCG, serum nicked hCG, serum nicked hypergly-
cosated hCG, serum asialo hCG, serum hCG free b-subunit
and serum nicked hCG b. hCG concentrations were
transformed to standard deviation scores adjusted to ges-
tational age at blood sampling [19].
Fetal growth and birth weight
Early fetal growth was estimated by ultrasound measure-
ment of crown-rump length (CRL) in a subset of women
(N = 1526) which had a reliable and regular menstrual
cycle [18, 19]. CRL values were transformed to standard
deviation scores adjusted to gestational age of pregnancy
determined according to the last menstrual period (LMP).
CRL was measured by ultrasound in early pregnancy, in a
true mid-sagittal plane with the genital tubercle and the
fetal spine longitudinally in view [20]. The maximum
length from cranium to the caudal rump was measured as a
straight line [20].
Fetal weight was estimated by ultrasound measurements
in the period of 18–25th week of pregnancy (me-
dian = 20.5 week, 95 % range 18.5–23.4 week;N = 7471)
and after the 25th week of pregnancy (median = 30.3 week,
95 % range 28.3–33.0 week; N = 7641) and estimations for
fetal weight were transformed to standard deviation scores
adjusted to gestational age of pregnancy determined by
crown-rump length and biparietal diameter, as has been
described previously [20]. Information on birth weight was
obtained from community midwives, obstetricians and
hospital registries. Birth weight standard deviations scores,
adjusted for gestational age, were constructed using the
Niklasson percentile growth curves [21]. Small for gesta-
tional age at birth (SGA) was defined as a standardized birth
weight lower than the 10th percentile of the study population.
Covariates
Information on maternal age, smoking status, educational
level and ethnicity was obtained by questionnaires during
pregnancy. Ethnicity was determined by the country of
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origin and was defined according to the classification of
Statistics Netherlands [18]. Maternal smoking was classi-
fied as no smoking, smoking until known pregnancy and
continued smoking during pregnancy. Information on fer-
tility treatment, parity, placental weight at birth and sex of
the child was obtained from community midwives, obste-
tricians, and hospital registries. Gestational weight gain
was defined as the difference between self-reported
maternal weight before pregnancy and maternal weight
measured in the third trimester (a sensitivity analysis using
maternal weight measured in early pregnancy and in the
third trimester did not reveal more confounding potential or
explained variability of the model). Free thyroxine (FT4)
and thyroid stimulating hormone (TSH) were available in a
subset of 5498 pregnant women during early pregnancy
[22].
Statistical analysis
We investigated the association of hCG concentrations
with CRL within a subset group of women (with regular
cycles and known last menstrual period) and birth weight
within the whole group by using multiple linear regres-
sion analysis with restricted cubic splines utilizing three
knots. Multivariable associations were graphically depic-
ted by plots (main manuscript) and the key b estimates
with 95 % confidence intervals are shown in Supple-
mental Table 3. We tested for effect modification with
gestational age at blood measurement and fetal sex by
introducing a product interaction term of hCG and ges-
tational age at blood sampling or fetal sex to the model.
Given the fetal growth differences across gestational age
and between male and female fetuses, a P value of\0.15
was considered for stratification. We subsequently strati-
fied the analyses by quintiles of gestational age at blood
sampling and in the case of a difference between these
time points, further stratification was performed per one
or more gestational weeks. To study the association of
hCG with the risk of SGA we used multiple logistic
regression models with restricted cubic splines utilizing
three knots. The association of hCG concentrations with
fetal growth throughout gestation was analyzed using
unbalanced repeated measurement regression models for
which the outcome consisted of standardized estimated
fetal weight in the second and third trimester and stan-
dardized birth weight. These models take the correlation
between repeated measurements of the same subject into
account and allow for incomplete outcome data [23]. We
used an unstructured covariance matrix with fixed effects,
and added the interaction term of hCG with the time
component (gestational age) in the models, and adjusted
for covariates. Based on the size of effect estimate dif-
ferences and biological plausibility extracted from the
literature, we stratified these analyses in a similar manner
as previously described analyses on birth weight. Lower
statistical power in subsequent subset analyses and the
need for testing three-way interactions were deemed sta-
tistically not viable. The hCG cut-off in the repeated
measurement analyses was chosen based on the optimal
power necessary for the biologically plausible reference
group.
All model covariates were selected based on biological
plausibility, change in effect estimate of interest or residual
variability of the model. All analyses were adjusted for
maternal age, smoking status, BMI, parity, educational
level, ethnicity, fetal sex, placental weight at birth, gesta-
tional age at blood sampling and gestational weight gain of
the mother. Placental weight, as a marker for trophoblast
cell mass, may be an important determinant of both hCG
concentrations [19] and fetal growth and from that reason
was adjusted for in the models. Maternal weight gain was
taken as a proxy for the potential confounding effects of
hyperemesis gravidarum (HG). Gestational weight change
is an important clinical marker of the HG effects [24] and
the same goes for other symptoms of HG such as
reflux/belching, nausea and vomiting—but addition of
these factors did not change our models.
For covariates with missing data, multiple imputation
according to the Markov Chain Monte Carlo method was
used [25]. Five imputed data sets were created and pooled
for the analysis. Maternal smoking, education, ethnicity,
BMI, parity, placental weight, gestational weight gain and
fetal sex were added to the model. Furthermore, we added
gestational age at blood sampling, hCG level and maternal
FT4 level as prediction variables only. No statistically
significant differences in descriptive statistics were found
between the original and imputed datasets.
Statistical analyses were performed using Statistical
Package of Social Sciences version 21.0 for Windows
(SPSS Inc. Armonk, NY), R statistical software with RMS
package version 3.2.0 and SAS software for Windows
version 9.3.
Results
The final study population consisted of 7987 pregnant
women (Fig. 1), descriptive statistics of which are shown
in Table 1. Maternal hCG concentrations were measured at
the moment of inclusion in the study (median 14.4 weeks,
95 % range 10.1–26.2 weeks). In the study population, the
mean (±SD) birth weight was 3412.0 (±559.7) grams, the
mean gestational age at birth was 39.8 (±1.9) weeks, the
mean maternal age was 29.6 (±5.3) years, women were
predominantly nulliparous (55.3 %), non-smokers
(72.7 %) and of Dutch origin (46.6 %).
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The association of maternal hCG with birth weight
In the whole population, there was a non-linear association
of maternal hCG concentrations with birth weight
(Supplemental Fig. 1, P = 0.009) and the risk of SGA
(Supplemental Fig. 1, Supplemental Table 1). Considering
that hCG concentrations vary throughout gestation, we
investigated whether gestational age at blood sampling
Mothers with hCG measurement
N=8193
N=168 excluded
- Missing birth weight (N=78)
- In vitro fertilisation (N=38) 
- Twin pregnancies (N=90)
Final study population
N=7987
Mothers enrolled during pregnancy
N=8879
Unable to perform measurement 
mainly due to (non) availability of 
serum, discontinuation of study 
participation, lab measurement errors.
Fig. 1 Flowchart showing
selection procedure of study
population
Table 1 Descriptive statistics
of mother and child pairs
Characteristics Value
hCG, median (95 % range), IU/l, 35559.0 (6106.8–101808.5)
Birth weight, mean (SD), g 3412.0 (559.7)
Gestational age at blood sampling, median (95 % range), weeks 14.4 (10.1–26.2)
Gestational age at birth, mean (SD), weeks 39.8 (1.9)
Age, mean (SD), years 29.6 (5.3)
BMI, median (95 % range), kg/m2 23.9 (18.7–36.5)
Parity, n (%)
Nullipara 4531 (55.3)
Primipara 2475 (30.2)
Multipara 1187 (14.5)
Smoking status, n (%)
Non smokers 5953 (72.7)
Stopped smokers 691 (8.4)
Smokers 1549 (18.9)
Educational level, n (%)
No education or primary education 1046 (12.8)
Secondary education 3844 (46.9)
Higher education 3303 (40.3)
Ethnicity, n (%)
Dutch 3742 (46.6)
Moroccan 530 (6.6)
Turkish 710 (8.8)
Surinam 686 (8.5)
Other-European 598 (7.5)
Other-Non-European 1758 (21.9)
Fetal sex, n (%)
Male 4124 (50.3)
Female 4069 (49.7)
Gestational weight gain, mean (sd), kg 10.0 (5.1)
Placental weight at birth (g), median, (95 % range) 620.0 (390.0–950.0)
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modifies the association of hCG concentrations with birth
weight. After addition of a product interaction term to the
model (hCG*gestational age at blood sampling; P = 0.10),
we stratified the association of hCG concentration with
birth weight by gestational age at blood sampling (Fig. 2;
Supplemental Fig. 2). The association of hCG with birth
weight was present in the 11th week (Fig. 2, P = 0.03;
beta estimates shown in Supplemental Table 3) and 12th
week of pregnancy (Fig. 2, P = 0.002; Supplemental
Fig. 3), but not from the 13th week onwards (Fig. 2;
Supplemental Fig. 3). The association of hCG with the risk
of SGA showed a consistent trend with the results from
linear regression analysis with birth weight, with a ten-
dency of higher odds of SGA in low hCG concentrations in
the 11th and 12th week (Fig. 2 and Supplemental Fig. 3).
The odds of SGA in women with low hCG concentration
measured in the 11th and 12th week (\5th to\15th per-
centile) were 1.80 to 2.21-fold higher than the reference
group (Supplemental Table 2).
Subsequently, we set out to investigate if the association
of hCG with birth weight occurs due to changes during
early pregnancy (crown rump length) or also due to
changes in the second half of pregnancy (fetal growth).
The association of maternal hCG with crown rump
length
In the subset of women with regular cycles and known last
menstrual period, in which CRL measurement was avail-
able, hCG concentrations during early pregnancy were
negatively associated with CRL, but this analysis did not
reach statistical significance (Supplemental Fig. 4;
N = 1526; P for interaction fetal sex = 0.10).
The association of maternal hCG with fetal growth
Maternal hCG concentrations were associated with esti-
mated fetal weight in the whole population, but this asso-
ciation was most prominent in pregnancies in which hCG
was measured in the 12th week of gestation (Table 2). The
association between hCG concentrations measured in the
12th week of pregnancy and estimated fetal weight is
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Fig. 2 Plots show the linear regression models for total hCG
(standardized according to gestational age at measurement; SD) and
birth weight (standardized according to gestational age at birth; SD), as
well as the logistic regression model for hCG and birth weight small for
gestational age (defined as birth weight below 10th percentile for
gestational age) as predicted mean with 95 percent confidence interval.
Analyses were performed after exclusion of women with IVF treatment
(N = 38), twin pregnancy (N = 90) and were adjusted for maternal
age, smoking, BMI, parity, placental weight at birth, education level,
ethnicity, gestational weight gain and fetal sex
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illustrated in Fig. 3. The estimated fetal weight in women
with a relatively high hCG concentration (Fig. 3, 3rd ter-
tile, depicted by the dotted line) was lower in mid preg-
nancy but accelerated throughout gestation, finally
reaching a birth weight similar to the reference group (2nd
tertile). In contrast, estimated fetal weight in women with a
low hCG concentration (Fig. 3, 1st tertile, depicted by the
solid line) was similar in mid-pregnancy, but was associ-
ated with lower birth weight than the reference group after
a decrease of fetal growth in the second half of pregnancy.
Sex-specific differences in the association of hCG
with birth weight and fetal growth
Considering the biological differences in fetal growth and
in hCG physiology between male and female fetuses, we
tested for effect modification by fetal sex. After addition of
a product interaction term to the model (hCG*fetal sex;
P = 0.10), we stratified analyses according to fetal sex.
The association of hCG concentrations (measured in week
11–12) and birth weight did not differ for fetal sex (Sup-
plemental Fig. 5 and 6). However, in women with low hCG
concentrations (\10th or \15th percentile), the risk of
SGA was higher in male than in female fetal-sex (Sup-
plemental Table 4).
The association of hCG concentrations with estimated
fetal weight differed according to fetal sex (Supplemental
Table 5). In women with relatively low hCG during the late
first trimester (Fig. 4, 1st tertile, depicted by the solid
lines), estimated fetal weight in mid-pregnancy was overall
lower in male than in female fetuses. However, in female
fetuses, low maternal hCG was associated with a greater
Table 2 The association of
maternal hCG with fetal growth
throughout gestation
Beta ±SE P value 95 % Confidence interval Number of participants per week
hCG in all 0.002 ±0.001 0.0017 (0.001, 0.003)
hCG stratified per week of measurement
11th week -0.001 ±0.003 0.81 (-0.007, 0.005) 254
12th week 0.007 ±0.002 0.0002 (0.003, 0.010) 783
13th week 0.000 ±0.001 0.94 (-0.003, 0.003) 1412
14th week 0.000 ±0.002 0.78 (-0.003, 0.004) 1060
Table shows the effects estimates of repeated measurement model for the association of total hCG (s-
tandardized according to gestational age at measurement; SD) with fetal growth (standardized estimated
fetal weight measured using ultrasound in mid pregnancy (18–25 weeks), late pregnancy ([25 weeks) and
birth weight), as beta estimate with standard error. Analyses were performed after exclusion of women with
IVF treatment (N = 38), twin pregnancy (N = 90) and were adjusted for maternal age, smoking, BMI,
parity, education level, ethnicity, gestational weight gain, placental weight at birth and fetal sex
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Fig. 3 Graph depicts the beta estimates from a repeated measurement
model of the association of total hCG (standardized according to
gestational age at measurement; SD) with fetal growth (standardized
estimated fetal weight measured using ultrasound in mid pregnancy
(18–25 weeks), late pregnancy ([ 25 weeks) and birth weight).
Analyses were performed after exclusion of women with IVF
treatment (N = 38), twin pregnancy (N = 90) and were adjusted
for maternal age, smoking, BMI, parity, education level, ethnicity,
gestational weight gain, placental weight at birth and fetal sex
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deceleration of fetal growth than in male fetuses
(-0.17 SD decrease in male fetus pregnancies versus
-0.26 SD decrease in female fetus pregnancies; Fig. 4).
In women with high hCG concentrations during the late
first trimester (Fig. 4, 3rd tertile, depicted by the dotted
lines), estimated fetal weight during mid-pregnancy was
overall lower in female than in male fetuses. However, in
female fetuses, high maternal hCG concentrations were
associated with an acceleration of fetal growth as compared
to a slight deceleration in male fetus pregnancies
(-0.07 SD decrease in males versus ?0.26 SD increase in
females; Fig. 4).
There was no effect modification by, or change in the
results after adjustment for maternal FT4 and TSH con-
centrations (data not shown).
Discussion
Our study shows that low hCG concentrations in the late
first trimester are associated with lower birth weight and an
increased risk of SGA. We demonstrate that the association
of low hCG concentrations in the late first trimester with
lower birth weight arises due to a decrease in fetal growth
during the second half of pregnancy. In contrast, high
concentrations of hCG in the late first trimester were
associated with growth acceleration which resulted in a
normal birth weight. A low hCG concentration was asso-
ciated with a decrease in fetal growth, independent of fetal
sex. However, high hCG concentrations were associated
with an accelerated fetal growth in female, but not in male
fetuses.
Fetal growth and birth weight reflect intrauterine con-
ditions during pregnancy. Major healthcare problems such
as cardiovascular diseases and type 2 diabetes are preor-
dained in utero and low birth weight is one of the main
determinants of those disorders [5, 6]. Previous studies that
investigated hCG as a potential determinant of fetal growth
restriction mostly focused on either the first or second tri-
mester. Furthermore, most of those studies examined only
the association of the b-hCG isoform and fetal growth,
meaning that non-measured differences in other important
active hCG-isoforms could have influenced the results [26].
A large Danish study of 9450 women in the 8th–13th week
of pregnancy reported that a low free b-hCG concentration
is associated with SGA [27]. A study of 8012 pregnant
women by Krantz et al. reported that a low free b-hCG
concentration in the 10th–13th week of pregnancy is
associated with an increased risk of fetal growth restriction
(FGR) [28]. Amongst 100 women, Abdel Moety et al. also
reported that low concentrations of free b-hCG measured
in the 11th to 14th week of gestation are associated with
FGR [29]. In contrast, other studies showed that a high
hCG concentration in the second trimester is associated
with a decrease in fetal growth and/or FGR [16, 17]. To
date, no study had investigated the association of total hCG
with fetal growth or investigated the role of gestational age
of hCG measurement and/or fetal sex in this association.
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Fig. 4 The association of maternal hCG in 11th or 12th week with fetal growth stratified by fetal sex
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In the current study, low hCG concentrations were only
associated with low birth weight when hCG was measured
in the 11th or 12th week of gestation, suggesting that hCG
has a specific role in fetal growth during the transitional
period from the first to the second trimester. This period
marks the start of maternal blood supply in the intervillous
space and the end of the hypoxic fetal environment [30].
Oxidative stress in early gestation is a risk factor for
adverse pregnancy outcomes including fetal growth
restriction, which might be due to a lack of antioxidant
enzymes in fetal tissues at that time [31]. hCG is indirectly
involved in the maintenance of early pregnancy hypoxia
via regulating endocrine gland-derived vascular endothelial
growth factor (EG-VEGF), a factor that at least partially
ensures physiologically low oxygen concentrations during
early pregnancy through stimulation of the arterial plugs
formation [9]. The specific association in the current study
of low hCG in the late first trimester with decreased fetal
growth might be due to a suboptimal development of the
trophoblast shell and arterial plugs, or an earlier release of
the arterial plugs via lower levels of EG-VEGF. This could
potentially expose the fetus to the harmful effects of O2
free radicals. Further studies are needed to replicate our
findings and investigate the association of repeatedly
measured hCG concentrations with fetal growth.
Studies have shown that fetal growth and maternal hCG
concentrations differ depending on fetal sex. hCG con-
centrations in pregnancies with a female fetal sex are
higher from as early as the third post-fertilization week
[32–35]. In this study, the continuous association of hCG
concentrations measured at the end of the first trimester
with birth weight did not differ between pregnancies with a
male or female fetus. Nevertheless, low hCG concentra-
tions were associated with a higher risk of SGA in male
fetal sex. This discrepancy already suggests that there is a
fetal sex-specific association of hCG with fetal growth
patterns. Moreover, further analyses revealed that the
association of low hCG during the late first trimester with
fetal growth deceleration was stronger in female fetal sex.
Furthermore, high hCG concentrations during the late first
trimester were associated with growth acceleration in the
female, but not male fetuses.
Male fetuses may be more susceptible to the impact of
relatively low hCG concentrations during the late first tri-
mester than female fetuses, considering the fact that mean
hCG concentrations are lower in pregnancies with a male
fetus [32, 33]. On the other hand, our findings show that the
association of low hCG concentrations with decreased fetal
growth is present in both female and male fetal sex. This
suggests that low hCG concentrations during the first tri-
mester have an impact on the fetal growth trajectory
independent of fetal sex. Interestingly, the main difference
between males and females in the current study was the
association of high late first trimester hCG with growth
acceleration during mid-pregnancy, which was only pre-
sent in female fetuses. This might be due to the higher
concentrations of hCG in female fetal sex, or due to fetal
sex-specific differences in hCG isoforms [19]. Future
studies are needed to investigate the mechanisms that
underlie the differential effects of female fetal sex in the
association of hCG and fetal growth in more depth. In
addition, replication of fetal sex-specific differences in the
association of hCG with fetal growth will be required,
preferably in samples that have adequate power to test for
higher order interactions.
The strengths of the current study include the avail-
ability of hCG concentrations as well as detailed fetal
growth data with serial fetal weight measurements in a
large population. The fact that hCG measurements were
also available across a wide gestational time span, enabled
us to observe a change in the association of hCG with fetal
growth across gestational age. We were, however, limited
by the fact that a single hCG measurement was available.
As a consequence, we were not able to assess interindi-
vidual differences in the change of hCG concentrations
during pregnancy. Also, the observational nature of this
study does not allow for inference of causality and does not
preclude the existence of residual confounding. As such, it
is possible that it is the fetal size that affects maternal hCG
concentration and/or that placental growth plays a con-
founding or mediating role. However, the latter seems less
likely since the addition of placental weight to the model
did not cause any meaningful changes in effect estimates.
In conclusion, we demonstrate that late first trimester
hCG concentrations are associated with fetal growth and
birth weight. In women with low hCG concentrations
during the late first trimester, fetal growth is lower result-
ing in a lower birth weight. In female fetal-sex pregnancies,
a high maternal hCG concentration at the end of the first
trimester is associated with fetal growth acceleration. The
underlying mechanism of these effects might involve a
flawed protection from oxidative stress due to effects of
hCG on arterial plug formation. Further research is nec-
essary to investigate the causality of this association and
the biological mechanism by which maternal hCG in the
late first trimester affects fetal growth.
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